InflaRx Future Growth
Future criteria checks 2/6
InflaRx is forecast to grow earnings and revenue by 35.3% and 65.8% per annum respectively while EPS is expected to grow by 41.1% per annum.
Key information
35.3%
Earnings growth rate
41.1%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 65.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely
Jun 25We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1 | -60 | -20 | -16 | 3 |
12/31/2025 | 1 | -73 | -93 | -89 | 3 |
12/31/2024 | 0 | -57 | N/A | -51 | 3 |
9/30/2024 | 0 | -57 | -48 | -48 | N/A |
6/30/2024 | 0 | -47 | -43 | -43 | N/A |
3/31/2024 | 0 | -41 | -42 | -42 | N/A |
12/31/2023 | 0 | -43 | -38 | -38 | N/A |
9/30/2023 | 0 | -35 | -32 | -32 | N/A |
6/30/2023 | N/A | -35 | -30 | -30 | N/A |
3/31/2023 | N/A | -27 | -32 | -31 | N/A |
12/31/2022 | N/A | -29 | -34 | -34 | N/A |
9/30/2022 | N/A | -34 | -40 | -40 | N/A |
6/30/2022 | N/A | -38 | -47 | -47 | N/A |
3/31/2022 | N/A | -54 | -42 | -42 | N/A |
12/31/2021 | N/A | -46 | -40 | -40 | N/A |
9/30/2021 | N/A | -42 | -38 | -38 | N/A |
6/30/2021 | N/A | -37 | -37 | -37 | N/A |
3/31/2021 | N/A | -32 | -37 | -36 | N/A |
12/31/2020 | N/A | -34 | -37 | -37 | N/A |
9/30/2020 | N/A | -39 | -43 | -43 | N/A |
6/30/2020 | N/A | -46 | -43 | -43 | N/A |
3/31/2020 | N/A | -52 | -46 | -45 | N/A |
12/31/2019 | N/A | -53 | -44 | -43 | N/A |
9/30/2019 | N/A | -50 | -34 | -33 | N/A |
6/30/2019 | N/A | -42 | -30 | -29 | N/A |
3/31/2019 | N/A | -29 | -25 | -24 | N/A |
12/31/2018 | N/A | -30 | -22 | -22 | N/A |
9/30/2018 | N/A | -31 | -20 | -19 | N/A |
6/30/2018 | N/A | -29 | N/A | -18 | N/A |
3/31/2018 | N/A | -31 | N/A | -15 | N/A |
12/31/2017 | N/A | -24 | N/A | -12 | N/A |
9/30/2017 | N/A | -17 | N/A | -10 | N/A |
6/30/2017 | N/A | -15 | N/A | -8 | N/A |
3/31/2017 | N/A | -12 | N/A | -7 | N/A |
12/31/2016 | N/A | -9 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IFRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IFRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IFRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IFRX's revenue (65.8% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: IFRX's revenue (65.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IFRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 11:37 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InflaRx N.V. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Kumar | Baird |
Mayur Somaiya | BMO Capital Markets Equity Research |
Madhu Kumar | B. Riley Securities, Inc. |